{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-002996","form_type":"8-K","ticker":"STIM","cik":"0001227636","company_name":"Neuronetics, Inc.","filed_at":"2023-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.118545+00:00","generated_at":"2026-06-18T09:21:31.935237+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Neuronetics reports record Q4 2022 revenue $18.2M (+21% YoY); full year $65.2M","bullets":["Q4 revenue $18.2M, up 21% YoY; US treatment session revenue record $12.5M.","Full year net loss ($37.2M) or ($1.38) per share vs ($31.2M) or ($1.22) in 2021.","Cash $70.3M at year-end; guides Q1 2023 revenue $15-16M, FY2023 $66-72M.","Expanded Greenbrook partnership through 2028; NGS policy allows NPs to order TMS.","Peer-reviewed publication shows NeuroStar TMS effective for anxious depression."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-002996","json":"https://secwatch.observer/filing/0001558370-23-002996.json","markdown":"https://secwatch.observer/filing/0001558370-23-002996.md","text":"https://secwatch.observer/filing/0001558370-23-002996.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1227636/000155837023002996/0001558370-23-002996-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1227636/000155837023002996/stim-20230307x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T09:21:31.935237+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d1687d18dfe1fb3c4453c36a9a1467b3d91c7624","claim":"Neuronetics, Inc. reported the three months ended December 31, 2022 and the year ended December 31, 2022 results: revenue $65.2 million.","evidence_excerpt":"of $12.5 million in the fourth quarter 2022 ● Increased NeuroStar System revenue 64% over the fourth quarter of 2021 ​ ​ Full Year 2022 Highlights ● Full year 2022 revenue of $65.2 million, representing an 18% increase as compared to full year 2021 ● Full year 2022 U.S. treatment session revenue of $45.1 million ● Full year 2022 U.S. NeuroStar Advanced Therapy","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1227636/000155837023002996/0001558370-23-002996-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2022 and the year ended December 31, 2022"},{"label":"Revenue","value":"$65.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}